Nanoparticle-based next-generation influenza vaccines

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Head, Molecular Immunoengineering Unit, Viral Pathogenesis Laboratory, Vaccine Research Center, NIAID
    Biography

      Dr. Kanekiyo serves as Scientific Lead of the Influenza Program at the Vaccine Research Center (VRC), NIAID, NIH. In this role, he leads scientific research on basic, preclinical, and translational aspects of candidate influenza vaccines developed in the VRC. In addition, he is Head of Molecular Immunoengineering Unit, in which his team tackles complex immunology and vaccinology questions utilizing techniques in immunoengineering, protein engineering, molecular virology, synthetic biology, structural biology, and biochemistry. Dr. Kanekiyo is an immunologist, and a virologist who studies vaccine technologies, viral immunity, and host pathogen interaction. His work is centered on influenza virus, herpesvirus, and (re)emerging viruses. Dr. Kanekiyo obtained his D.V.M. from the Nihon University, Japan in 2002, and earned his Ph.D. in Veterinary Medicine with concentration on Molecular and Microbiology at the Nihon University Graduate School of Veterinary Medicine in 2006. Prior to the current appointment he was a postdoctoral fellow in the laboratory of Dr. Gary Nabel at the VRC focusing on HIV and influenza immunogen design. Dr. Kanekiyo is an inventor of several vaccine related technologies including the self-assembling nanoparticle-based influenza vaccines, that are currently evaluated in human phase I clinical trials.


    Abstract

    Most currently used conventional influenza vaccines are based on 1940s technology. Advances in immunogen design and vaccine delivery emerging over the last decade open novel opportunities for improving influenza vaccines that are previously inaccessible. These next-generation vaccine design tools are particularly promising in their potential to provide solutions to challenging targets for which conventional approaches have proven ineffective—for example, a universal influenza vaccine. Among the new vaccine technologies, nanoparticle-based vaccines have unique properties that are highly designable and programable. I will discuss our efforts on the development of next-generation nanoparticle-based influenza vaccines to elicit broad and potent protective immunity to influenza virus. A few of such designed nanoparticle-based influenza vaccine candidates are currently evaluated in human clinical trials.

    Learning Objectives:

    1. Nanoparticle-based immunogen design to elicit broad and potent protective immunity to influenza virus

    2. How immunofocusing to the viral sites of vulnerability can be achieved through immunogen design


    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    MAR 16, 2021 10:00 AM PDT
    C.E. CREDITS
    MAR 16, 2021 10:00 AM PDT
    Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
    APR 21, 2021 10:00 AM PDT
    C.E. CREDITS
    APR 21, 2021 10:00 AM PDT
    Date: April 21, 2021 Time: 10:00am (PDT), 1:00pm (EDT) Serological testing for SARS-CoV-2 has been steadily adopted into clinical practice over the course of this pandemic. In this webinar,...
    APR 01, 2021 8:00 AM PDT
    C.E. CREDITS
    APR 01, 2021 8:00 AM PDT
    Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
    Loading Comments...
    Show Resources